Abstract:
Colorectal cancer (CRC) remains the second-leading cause of cancer deaths globally, with approximately 1 million annual fatalities. Our innovative research applies integrated systems glycobiology to identify non-invasive prognostic markers crucial for improving patient outcomes.
Our comprehensive multi-omics approach—combining glycomics, glyco/proteomics, and transcriptomics—revealed that non-canonical paucimannosidic proteins create distinctive glyco-signatures in CRC tumors, originating from both tumor-infiltrating monocytes and cancer cells.
The study identified hexosaminidase subunit beta as a key truncating glyco-enzyme overexpressed in CRC tumors that facilitates paucimannosidic protein formation. Importantly, plasma hexosaminidase activity demonstrated significant correlation with five-year survival rates in a large CRC patient cohort.
This research showcases the untapped potential of multi-omics approaches to precisely map glycosylation changes during tumor development, unveiling promising new biomarkers for CRC risk stratification and potentially other cancers.
Takeaways:
- Discover the significance of non-invasive prognostic markers in colorectal cancer (CRC) and their potential to improve clinical decision-making and patient survival.
- Explore the integrated systems glycobiology approaches used in the study to identify new glyco-markers in CRC patient specimens through multi-omics data analysis.
- Understand the role of non-canonical paucimannosidic proteins and their origins from tumor-infiltrating monocytes and cancer cells in creating glyco-signatures associated with CRC.
- Learn how plasma hexosaminidase activity correlates with the five-year survival rates of CRC patients, highlighting the clinical implications of these findings."
Speakers
Cory E. Muraco
Merck
Senior Global Product Manager, Large Molecule Reference Materials
Cory joined the company in 2013, starting in the Chemical Standards division, developing and validating analytical methods for testing the purity of certified reference materials using GC and LC methods. After serving in several R&D and Marketing roles, in 2024, he assumed his current role where he is in charge of the design and execution of the company's large molecule reference material strategy.
Professor Morten Andersen
Macquarie University
Associate Professor
A/Prof Morten Andersen obtained a PhD in Protein Chemistry in 2009 from Univ Southern Denmark and thereafter relocated to Australia to complete two fellowships awarded by the Danish Research Agency and Australian Research Council. Enabled by a Cancer Institute NSW fellowship (2014-17), he then established the Analytical Glycoimmunology lab at Macquarie Univ, Sydney, Australia. He is currently a tenured ARC Future Fellow (2022-26) at Macquarie Univ and was recently recruited to the Institute for Glyco-Core Research (Nagoya Univ, Japan) as Visiting Professor to establish a satellite lab in clinical glycoproteomics (2022-27). Andersen's research team develops and applies innovative MS-based glycomics and glycoproteomics methods for the comprehensive profiling of the heterogenous glycoproteome, which opens new avenues to decode the role of glycoproteins in complex biological processes. His current research program in glycoimmunology focuses on the innate immune system and immune disorders including inflammation (sepsis), host-pathogen interactions and cancer.
Research and disease areas
- Metabolism research
期间:1h 15min
语言:English
场次 1:往期 June 17, 2025
如要继续阅读，请登录或创建帐户。
暂无帐户？